Tiotropium Boosts Lung Function in Early COPD (CME/CE)

(MedPage Today) -- Higher FEV1 at 24 months in Chinese study, but long-term impact unclear
Source: MedPage Today Pulmonary - Category: Respiratory Medicine Source Type: news

Related Links:

Publication date: July 2020Source: The Lancet Respiratory Medicine, Volume 8, Issue 7Author(s): Matthew Moll, Phuwanat Sakornsakolpat, Nick Shrine, Brian D Hobbs, Dawn L DeMeo, Catherine John, Anna L Guyatt, Michael J McGeachie, Sina A Gharib, Ma'en Obeidat, Lies Lahousse, Sara R A Wijnant, Guy Brusselle, Deborah A Meyers, Eugene R Bleecker, Xingnan Li, Ruth Tal-Singer, Ani Manichaikul, Stephen S Rich, Sungho Won
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Publication date: July 2020Source: The Lancet Respiratory Medicine, Volume 8, Issue 7Author(s): Daiana Stolz
Source: The Lancet Respiratory Medicine - Category: Respiratory Medicine Source Type: research
Conditions:   Pulmonary Disease, Chronic Obstructive;   Smoking Intervention:   Behavioral: Proactive Outreach Sponsor:   VA Office of Research and Development Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Is there a possible link between COPD, lung function, and the risk for developing type 2 diabetes?BMC Pulmonary Medicine
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Pulmonary Medicine Journal Article Source Type: news
BackgroundIn contrast to Western medicine which currently offers no approved pharmacotherapy options for cachexia, in Japan multi-component extracts of medicinal plants are used with coverage by the national health insurance. This so called “Kampo” medicine is an example of the modern concept of multi-component/multi-target therapy. For the three traditional preparations Hochuekkito (補中益気湯), Juzentaihoto (十全大補湯), and Rikkunshito (六君子湯), a multitude of clinical research data relating to cachexia has been published. These preparations are also referred to as “Hozai” (補剤...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Neutrophil elastase (NE) is a major protease in the airways of patients with cystic fibrosis (CF) that activates airway inflammation by several mechanisms. NE stimulates epithelial toll like receptors (TLR) resulting in cytokine upregulation and release, upregulates MUC5AC, a major airway mucin, degrades both phagocytic receptors and opsonins resulting in both neutrophil and macrophage phagocytic failure, generates oxidative stress via extracellular generation and uptake of heme free iron, and activates other proteases. Altogether, these mechanisms create a significant inflammatory challenge that impairs innate immune func...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conditions:   COPD;   COPD Exacerbation Intervention:   Behavioral: patient education, training booklet, 3 months tele health Sponsor:   Pamukkale University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Obstructive Pulmonary Disease Interventions:   Dietary Supplement: Fiber Inulin;   Dietary Supplement: Placebo Maltodextrin Sponsor:   Texas A&M  University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Obstructive Pulmonary Disease Intervention:   Behavioral: Advance directives Sponsor:   Centre Hospitalier René Dubos Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   COPD Exacerbation Intervention:   Drug: Prednisolone Sponsors:   University of Oxford;   National Institute for Health Research, United Kingdom Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: China Health | Chronic Obstructive Pulmonary | Respiratory Medicine | Spiriva | Study | Tiotropium